Basel, Switzerland, 01 June, 2020 – FoRx Therapeutics, a recently incorporated privately-held company developing first-in-class compounds for cancer treatment, today announces the appointment of Ulrich Lücking, PhD, as Head of Chemistry.
FoRx Therapeutics AG Raises EUR 10 Million Seed Round
First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer
Seasoned Biotech Executive Colin Goddard Joins as Executive Chairman
Basel, Switzerland, 22 April, 2020 – FoRx Therapeutics AG (FoRx), the biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways, today announced the closing of a EUR 10 million seed financing led by M Ventures (venture capital arm of Merck), Novartis Venture Fund and Omega Funds. Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE) and LSP (Life Sciences Partners) also joined the seed financing. The company also announces the appointment of Colin Goddard as Executive Chairman.
Write your email address to join the newsletter.